#OHIP+: ChildrenandYouthPharmacare, #Dr.EricHoskins, OntarioDrugBenefitprogram, ExceptionalAccessProgram
Ottawa, Jan 2 (Canadian-Media): With Ontario's one of the biggest expansion of medicare in Ontario families by its launching of OHIP+: Children and Youth Pharmacare yesterday, Ontario became the first province to provide more than 4,400 prescription medications free for children and youth age 24, media reports said.
“We believe in helping all families receive the medication they need, at no cost, to stay healthy and strong regardless of income. OHIP+ is a bold step toward our commitment and vision of bringing universal drug coverage to all Ontarians,” Dr. Eric Hoskins, Ontario Minister of Health and Long-Term Care was reported to state.,
Dr Eric Hoskins: Facebook
Through OHIP+, young people can reportedly access more than 4,400 drug products reimbursed under the Ontario Drug Benefit program -- one of the most generous drug benefit programs in Canada, providing coverage for over 4,400 drug products, including nutrition products and diabetic testing agents
This list would reportedly also include some of the most commonly used medications and those available through the Exceptional Access Program qualified individuals free of cost.
The Exceptional Access Program reportedly enables access to drugs not funded on the Ontario Drug Benefit Formulary or where no appropriate alternative is available on the Ontario Drug Benefit Formulary.
Qualified people would only be required to present their Ontario health card number along with a valid prescription at an Ontario pharmacy and medicine will be provided free of charge.
Medications covered by OHIP+ include asthma inhalers, drugs for treatment of depression, anxiety, epilepsy and attention deficit hyperactivity disorder, antibiotics, EpiPens (epinephrine auto-injectors), insulin, diabetes test strips, oral contraceptives, medications to treat some childhood cancers and other rare conditions, and many others.
Ontario's new medication coverage tool enables people to search to see if their drugs are covered under OHIP+.
(Reporting by Asha Bajaj)